Novel pro-survival mechanisms of PIM2 in multiple myeloma
PIM2 在多发性骨髓瘤中的新的促生存机制
基本信息
- 批准号:10668651
- 负责人:
- 金额:$ 59.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-15 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAffectAmerican Cancer SocietyBindingBinding ProteinsBiologicalBiological AssayBone MarrowBone Marrow NeoplasmsCell DeathCell SurvivalCellsCessation of lifeCodeComplexDataDevelopmentDisease ProgressionDown-RegulationFamilyGene ExpressionGenesGenetic TranscriptionHematologic NeoplasmsHomeostasisMalignant NeoplasmsMessenger RNAMetabolismMitochondriaModelingMolecularMultiple MyelomaNon-Hodgkin&aposs LymphomaOncogenesOncogenicPIM1 genePathogenesisPatientsPhosphotransferasesPlasma CellsPlayProductionProliferatingProtein-Serine-Threonine KinasesProteinsReactive Oxygen SpeciesRegulationRegulatory ElementReportingResistanceRespirationRoleSerineSignal TransductionSmall Interfering RNASolidSolid NeoplasmSourceStimulusTestingTransactivationTreatment FailureUp-RegulationWorkc-myc Geneschemotherapeutic agentconstitutive expressioncurative treatmentsexperimental studyfatty acid oxidationinhibitorkinase inhibitorknock-downmitochondrial metabolismmutantnanomolarnew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticsoverexpressionprogramspromoterprotein expressionproto-oncogene protein pimresponsetherapeutic targettherapy resistant
项目摘要
Multiple myeloma (MM) comprises 20% of all hematologic malignancies, second only to non-Hodgkin’s
lymphoma, with 34,470 new cases and 12,640 deaths expected in 2022. Despite new therapeutics, MM remains
incurable for almost all patients. The primary cause of treatment failure is upregulation of pro-survival
mechanisms and progressively greater therapy resistance - thus defining these pro-survival responses will
identify key therapeutic targets. The PIM family of serine/threonine kinases (PIM1, PIM2 and PIM3) have been
shown to be oncogenic and overexpressed in a wide range of solid and hematological malignancies, with the
highest level of PIM2 overexpression seen with MM disease progression. PIM kinases are constitutively active,
and because the mRNA and protein have short half-lives their biological activity is dictated by regulation of their
expression. Importantly, it is currently assumed that biological effects of PIM kinases are entirely due to their
kinase activity. Bringing this assumption into question, we recently reported that the first-in-class PIM2-selective
non-ATP-competitive inhibitor JP11646 (JP) caused significantly greater suppression of MM proliferation and
viability compared to ATP-competitive PIM kinase inhibitors that equivalently inhibited PIM2 kinase activity. We
found that JP’s increased efficacy was not due to superior inhibition of kinase activity, but rather to an unexpected
downregulation of PIM2 gene and protein expression that did not occur with the ATP-competitive PIM2 kinase
inhibitors. These observations led to our central hypothesis that PIM2 has critical but previously unrecognized
kinase-independent (Ki) pro-survival function in MM – including maintaining high constitutive expression of the
PIM2 gene. Preliminary studies have found that kinase-dead PIM2 mutants retain significant pro-survival activity.
Mechanistically, we found that PIM2 stably interacts with the oncogene cMYC in MM cells and increases cMYC
binding to several gene promoters - including PIM2 itself. Moreover, a cMYC inhibitor downregulated PIM2
expression, suggesting a novel auto-regulatory loop where PIM2 stabilizes cMYC binding and trans-activation
of the PIM2 promoter – JP, but not ATP-competitive PIM kinase inhibitors, disrupts this loop. Additionally, we
found that SLC25A11 and UCP2 – two genes coding mitochondrial metabolite transporters – are regulated by
PIM2-cMYC axis in MM. Consistent with this, JP treatment or PIM2 knockdown selectively disrupted oxidative
mitochondrial respiration, which we show is dependent on fatty acid oxidation (FAO). We propose to test a novel
model of SLC25A11 and UCP2 overexpression reprogramming MM metabolism to favor FAO and promoting
MM survival. Since JP has similar effects in acute myeloid leukemia and in solid tumors, PIM2 Ki function in MM
may also occur to other cMYC-driven cancers. As such, inhibition of PIM2 Ki function may be a broadly applicable
approach to target oncogenic cMYC activity. The Specific Aims proposed are: 1). To determine the kinase-
independent mechanisms by which PIM2 supports MM survival, 2). To elucidate PIM2 auto-regulation in MM
cells, and 3).To establish how PIM2 regulates MM metabolism independent of its kinase activity.
1
多发性骨髓瘤(MM)占所有血液恶性肿瘤的20%,仅次于非霍奇金淋巴瘤。
淋巴瘤,预计2022年将有34,470例新发病例和12,640例死亡。尽管有新的治疗方法,MM仍然
几乎所有患者都无法治愈。治疗失败的主要原因是促生存基因的上调
机制和逐渐更大的治疗抗性-因此定义这些促生存反应将
确定关键治疗靶点。丝氨酸/苏氨酸激酶的PIM家族(PIM 1、PIM 2和PIM 3)已经被发现。
在广泛的实体瘤和血液恶性肿瘤中表现为致癌和过表达,
MM疾病进展时观察到的最高水平的PIM 2过表达。PIM激酶是组成型活性的,
由于mRNA和蛋白质的半衰期很短,它们的生物学活性取决于它们对蛋白质的调节。
表情重要的是,目前假设PIM激酶的生物学效应完全是由于它们的
激酶活性带着这个假设的问题,我们最近报道说,一流的PIM 2-选择性
非ATP竞争性抑制剂JP 11646(JP)对MM增殖的抑制作用显著更强,
与ATP竞争性PIM激酶抑制剂相比,其等效地抑制PIM 2激酶活性。我们
发现JP的增加的功效不是由于对激酶活性的上级抑制,而是由于
PIM 2基因和蛋白表达下调,这在ATP竞争性PIM 2激酶中没有发生
抑制剂的这些观察结果导致我们的中心假设,即PIM 2具有关键但以前未被认识到的功能。
MM中的激酶非依赖性(Ki)促生存功能-包括维持
PIM 2基因。初步研究发现,激酶死亡的PIM 2突变体保留了显着的促生存活性。
从机制上讲,我们发现PIM 2与MM细胞中的癌基因cMYC稳定相互作用,
与几个基因启动子结合-包括PIM 2本身。此外,cMYC抑制剂下调PIM 2,
表达,提示一种新的自调节环,其中PIM 2稳定cMYC结合和反式激活
的PIM 2启动子- JP,而不是ATP竞争性PIM激酶抑制剂,破坏这个循环。另外我们
发现SLC 25 A11和UCP 2--两个编码线粒体代谢物转运蛋白的基因--受
与此一致,JP处理或PIM 2敲低选择性地破坏了MM中的氧化还原酶。
线粒体呼吸,我们表明这是依赖于脂肪酸氧化(FAO)。我们打算测试一部小说
SLC 25 A11和UCP 2过表达重编程MM代谢以有利于FAO并促进
MM存活率。由于JP在急性髓性白血病和实体瘤中具有相似的作用,因此MM中PIM 2 Ki功能
也可能发生在其他cMYC驱动的癌症中。因此,PIM 2 Ki功能的抑制可能是广泛适用的治疗方法。
靶向致癌cMYC活性的方法。提出的具体目标是:1)。为了确定激酶-
PIM 2支持MM存活的独立机制,2)。阐明MM中的PIM 2自动调节
3)确定PIM 2如何独立于其激酶活性调节MM代谢。
1
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KELVIN P. LEE其他文献
KELVIN P. LEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KELVIN P. LEE', 18)}}的其他基金
Durable humoral immunity regulated by intrinsic CD28 function in plasma cells
浆细胞内在 CD28 功能调节持久体液免疫
- 批准号:
8892983 - 财政年份:2013
- 资助金额:
$ 59.66万 - 项目类别:
Durable humoral immunity regulated by intrinsic CD28 function in plasma cells
浆细胞内在 CD28 功能调节持久体液免疫
- 批准号:
9115028 - 财政年份:2013
- 资助金额:
$ 59.66万 - 项目类别:
Durable humoral immunity regulated by intrinsic CD28 function in plasma cells
浆细胞内在 CD28 功能调节持久体液免疫
- 批准号:
8439086 - 财政年份:2013
- 资助金额:
$ 59.66万 - 项目类别:
Extramural Research Facility Construction Projects. Ros*
校外研究设施建设项目。
- 批准号:
7000560 - 财政年份:2009
- 资助金额:
$ 59.66万 - 项目类别:
CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and Survival
CD28 介导的多发性骨髓瘤细胞增殖和存活的调节
- 批准号:
9260690 - 财政年份:2007
- 资助金额:
$ 59.66万 - 项目类别:
CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and Survival
CD28 介导的多发性骨髓瘤细胞增殖和存活的调节
- 批准号:
8133375 - 财政年份:2007
- 资助金额:
$ 59.66万 - 项目类别:
CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and Survival
CD28 介导的多发性骨髓瘤细胞增殖和存活的调节
- 批准号:
8692668 - 财政年份:2007
- 资助金额:
$ 59.66万 - 项目类别:
CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and Survival
CD28 介导的多发性骨髓瘤细胞增殖和存活的调节
- 批准号:
7213526 - 财政年份:2007
- 资助金额:
$ 59.66万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 59.66万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 59.66万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 59.66万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 59.66万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 59.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 59.66万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 59.66万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 59.66万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 59.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 59.66万 - 项目类别:
Studentship